Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Michael J. Wagner, Megan Othus, Sandip P. Patel, Chris Ryan, Ashish Sangal, Benjamin Powers, G. Thomas Budd, Adrienne I. Victor, Chung Tsen Hsueh, Rashmi Chugh, Suresh Nair, Kirsten M. Leu, Mark Agulnik, Elad Sharon, Edward Mayerson, Melissa Plets, Charles Blanke, Howard Streicher, Young Kwang Chae, Razelle Kurzrock

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Fingerprint

Dive into the research topics of 'Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)'. Together they form a unique fingerprint.

Medicine & Life Sciences